Pollak M - Search Results

1

A phenotype of IGFBP-3 knockout mice revealed by dextran sulfate-induced colitis.

Yancu D, Blouin MJ, Birman E, Florianova L, Aleynikova O, Zakikhani M, VanderMeulen H, Seidman E, Pollak M. Yancu D, et al. Among authors: pollak m. J Gastroenterol Hepatol. 2017 Jan;32(1):146-153. doi: 10.1111/jgh.13461. J Gastroenterol Hepatol. 2017. PMID: 27253188

2

Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist.

Pollak M, Blouin MJ, Zhang JC, Kopchick JJ. Pollak M, et al. Br J Cancer. 2001 Aug 3;85(3):428-30. doi: 10.1054/bjoc.2001.1895. Br J Cancer. 2001. PMID: 11487276 Free PMC article.

3

Growth inhibition of breast epithelial cells by celecoxib is associated with upregulation of insulin-like growth factor binding protein-3 expression.

Levitt RJ, Buckley J, Blouin MJ, Schaub B, Triche TJ, Pollak M. Levitt RJ, et al. Among authors: pollak m. Biochem Biophys Res Commun. 2004 Apr 2;316(2):421-8. doi: 10.1016/j.bbrc.2004.02.062. Biochem Biophys Res Commun. 2004. PMID: 15020235

4

A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model.

Majeed N, Blouin MJ, Kaplan-Lefko PJ, Barry-Shaw J, Greenberg NM, Gaudreau P, Bismar TA, Pollak M. Majeed N, et al. Among authors: pollak m. Oncogene. 2005 Jul 7;24(29):4736-40. doi: 10.1038/sj.onc.1208572. Oncogene. 2005. PMID: 15870705

5

Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells.

Camirand A, Zakikhani M, Young F, Pollak M. Camirand A, et al. Among authors: pollak m. Breast Cancer Res. 2005;7(4):R570-9. doi: 10.1186/bcr1028. Epub 2005 Apr 12. Breast Cancer Res. 2005. PMID: 15987464 Free PMC article.

6

Insulin-like growth factor receptor I targeting in epithelial ovarian cancer.

Gotlieb WH, Bruchim I, Gu J, Shi Y, Camirand A, Blouin MJ, Zhao Y, Pollak MN. Gotlieb WH, et al. Gynecol Oncol. 2006 Feb;100(2):389-96. doi: 10.1016/j.ygyno.2005.09.048. Epub 2005 Nov 21. Gynecol Oncol. 2006. PMID: 16300820

7

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells.

Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Zakikhani M, et al. Among authors: pollak m. Cancer Res. 2006 Nov 1;66(21):10269-73. doi: 10.1158/0008-5472.CAN-06-1500. Epub 2006 Oct 23. Cancer Res. 2006. PMID: 17062558

8

Association of total insulin-like growth factor-I, insulin-like growth factor binding protein-1 (IGFBP-1), and IGFBP-3 levels with incident coronary events and ischemic stroke.

Kaplan RC, McGinn AP, Pollak MN, Kuller LH, Strickler HD, Rohan TE, Cappola AR, Xue X, Psaty BM. Kaplan RC, et al. Among authors: pollak mn. J Clin Endocrinol Metab. 2007 Apr;92(4):1319-25. doi: 10.1210/jc.2006-1631. Epub 2007 Jan 30. J Clin Endocrinol Metab. 2007. PMID: 17264182

9

The hedgehog pathway inhibitor cyclopamine increases levels of p27, and decreases both expression of IGF-II and activation of Akt in PC-3 prostate cancer cells.

Levitt RJ, Zhao Y, Blouin MJ, Pollak M. Levitt RJ, et al. Among authors: pollak m. Cancer Lett. 2007 Oct 8;255(2):300-6. doi: 10.1016/j.canlet.2007.05.006. Epub 2007 Jun 28. Cancer Lett. 2007. PMID: 17602833

10

Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft.

Singh RP, Deep G, Blouin MJ, Pollak MN, Agarwal R. Singh RP, et al. Carcinogenesis. 2007 Dec;28(12):2567-74. doi: 10.1093/carcin/bgm218. Epub 2007 Oct 4. Carcinogenesis. 2007. PMID: 17916909

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

865 results

Search Page

Filters